Piramal Pharma Strengthens Biologics Portfolio with Yapan Bio Acquisition

In a significant move to enhance its capabilities in biologics, Piramal Pharma Ltd. completed the acquisition of an additional 40.67% stake in Yapan Bio Private Limited. The deal, valued at approximately 760 million Indian Rupees (about 7.95 million USD), increases Piramal's ownership share in Yapan Bio to 74%, transforming it from an associate to a wholly owned subsidiary.

Yapan Bio's Expertise

Yapan Bio, located in Hyderabad, specializes in the process development, characterization, and GMP-compliant manufacturing services tailored for Phase I and II clinical trials specifically for vaccines and biologics. This acquisition allows Piramal to leverage Yapan Bio's extensive expertise and infrastructure in the development and manufacture of complex biologics, including antibody-drug conjugates (ADCs).

Strategic Benefits of the Acquisition

This transaction aligns with Piramal Pharma’s long-term strategy to strengthen its foothold in the rapidly growing market for biologics. The integration of Yapan Bio's capabilities into Piramal’s broader service offering will allow the company to efficiently develop and scale up complex biological therapies. The subsidiary will operate within Piramal Pharma Solutions (PPS), the contract development and manufacturing organization (CDMO) segment of Piramal Pharma, thereby enhancing its service offerings.

Piramal Pharma aims to capitalize on the growing demand for sophisticated biologics. As stated by Peter DeYoung, CEO of Piramal Global Pharma, this investment not only reinforces the company’s growth strategy but also emphasizes a patient-centric approach by meeting the increasing global demand for complex biologics. The expertise offered by Yapan Bio will enable Piramal to support its partners in addressing this demand effectively.

Impact on ADCelerate™

Yapan Bio plays a crucial role in supporting ADCelerate™, PPS's integrated fixed-price platform that optimizes the development process for ADCs from research and development to GMP manufacturing. This comprehensive support enables rapid completion within a span of just 12 months, enhancing Piramal’s capacity to bring critical life-saving ADCs to market efficiently and reliably.

Conclusion

With this successful acquisition, Piramal Pharma is poised to leverage Yapan Bio's specialized capabilities while expanding its portfolio in the biologics landscape. By acting on its strategic vision, Piramal not only enhances its operational efficiency but also ensures that patients have uninterrupted access to essential therapies, continuing their mission of global health improvement through innovative solutions.

Piramal Pharma Ltd. operates across 17 global development and manufacturing facilities, providing a broad range of differentiated products and services. The integration of Yapan Bio into this network will undoubtedly augment both companies' capabilities, responding effectively to the demands of the pharmaceutical industry while prioritizing patient care.

For more information about Piramal Pharma Solutions, visit their official website and follow them on LinkedIn and Facebook.